Cargando…

BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?

Detalles Bibliográficos
Autores principales:	Chen, Lingdan, Liu, Chunli, Lu, Wenju, Wang, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233353/ https://www.ncbi.nlm.nih.gov/pubmed/32032498 http://dx.doi.org/10.1164/rccm.201912-2525LE

Ejemplares similares

Positron Emission Tomography: A Novel Approach to Detect Pulmonary Artery Hypertension at the Early Stage?
por: Tang, Ruidi, et al.
Publicado: (2020)

Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension
por: He, Wenjun, et al.
Publicado: (2022)

Reply to Chen et al.: BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Provencher, Steeve, et al.
Publicado: (2020)

Pulmonary Vasculature: A Target for COVID-19
por: Chen, Lingdan, et al.
Publicado: (2021)

BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart
por: Piquereau, Jérôme, et al.
Publicado: (2019)

EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition
por: Pullamsetti, Soni Savai, et al.
Publicado: (2019)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell–based Therapy
por: Wang, Zi-Hao, et al.
Publicado: (2023)

MicroRNA-133a impairs perfusion recovery after hindlimb ischemia in diabetic mice
por: Chen, Lingdan, et al.
Publicado: (2018)

Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
por: Zheng, Zhenzhen, et al.
Publicado: (2021)

Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study
por: Chen, Yuqin, et al.
Publicado: (2019)

Cognitive Dysfunction in Patients with Pulmonary Hypertension
por: Yuan, Ping, et al.
Publicado: (2022)

Correction to: Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study
por: Chen, Yuqin, et al.
Publicado: (2020)

Pulmonary Hypertension in Glycogen Storage Disease Type II
por: Li, Hui-Ping, et al.
Publicado: (2018)

TIMP-1: A Circulating Biomarker for Pulmonary Hypertension Diagnosis Among Chronic Obstructive Pulmonary Disease Patients
por: He, Wenjun, et al.
Publicado: (2022)

CD248 as a novel therapeutic target in pulmonary arterial hypertension
por: Xu, Tao, et al.
Publicado: (2020)

Chloroquine reduces Th17 cell differentiation by stimulating T-bet expression in T cells
por: Thome, Rodolfo, et al.
Publicado: (2020)

Learning curve and analysis of curative effects after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Hong, Cheng, et al.
Publicado: (2023)

BET Proteins as Attractive Targets for Cancer Therapeutics
por: Sarnik, Joanna, et al.
Publicado: (2021)

Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?
por: Wu, Yanjuan, et al.
Publicado: (2023)

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

Effect of COVID-19 in Pulmonary Hypertension
por: Jha, Ajay Kumar
Publicado: (2022)

circGSAP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
por: Sun, Xishi, et al.
Publicado: (2021)

The roles of interleukins in perfusion recovery after peripheral arterial disease
por: Chen, Lingdan, et al.
Publicado: (2018)

Rac1 is a novel therapeutic target in mantle cell lymphoma
por: Tian, Tian, et al.
Publicado: (2018)

Transcription factors T-bet/GATA-3/Foxp3 in peripheral blood of patients with chronic otitis media with effusion
por: Yang, Lin, et al.
Publicado: (2019)

Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
por: Sun, Xishi, et al.
Publicado: (2021)

CBLN2 rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus
por: Huang, Can, et al.
Publicado: (2018)

Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension
por: Satoh, Kimio, et al.
Publicado: (2018)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Weatherald, Jason, et al.
Publicado: (2021)

A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity
por: Burgoyne, Adam M., et al.
Publicado: (2020)

More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Ning, Dong, et al.
Publicado: (2020)

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension
por: Mohamed, Nura A., et al.
Publicado: (2016)

IGF-1 and GLP-1 signaling: potential therapeutic target for neurological disorders – correspondence
por: Gajwani, Neeraj, et al.
Publicado: (2023)

Reply to Tang et al.: Positron Emission Tomography: A Novel Approach to Detect Pulmonary Artery Hypertension at the Early Stage?
por: Park, Jun-Bean, et al.
Publicado: (2020)

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
por: Ramasamy, Karthik, et al.
Publicado: (2021)

Reply to Sun et al.: circGASP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
por: Sun, Yuan-Yuan, et al.
Publicado: (2021)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4bssv00k1vrnf4thrg71rjofha